Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
Price:
39.15 CNY
1.16%
Market Closed
Updated:
May 14, 2024
Tibet Rhodiola Pharmaceutical Holding Co
Pre-Tax Income
|
Tibet Rhodiola Pharmaceutical Holding Co
Pre-Tax Income Peer Comparison
Comparables:
1099
601607
600998
C
600511
000963
Competitive Pre-Tax Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
|
Pre-Tax Income
¥898.2m
|
CAGR 3-Years
24%
|
CAGR 5-Years
30%
|
CAGR 10-Years
40%
|
|
|
Sinopharm Group Co Ltd
HKEX:1099
|
Pre-Tax Income
¥19.4B
|
CAGR 3-Years
13%
|
CAGR 5-Years
11%
|
CAGR 10-Years
16%
|
|
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
Pre-Tax Income
¥7.1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
6%
|
CAGR 10-Years
8%
|
|
|
Jointown Pharmaceutical Group Co Ltd
SSE:600998
|
Pre-Tax Income
¥2.9B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
9%
|
CAGR 10-Years
17%
|
|
C
|
China National Medicines Corp Ltd
SSE:600511
|
Pre-Tax Income
¥2.9B
|
CAGR 3-Years
15%
|
CAGR 5-Years
8%
|
CAGR 10-Years
19%
|
|
|
Huadong Medicine Co Ltd
SZSE:000963
|
Pre-Tax Income
¥3.4B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
14%
|
See Also
What is Tibet Rhodiola Pharmaceutical Holding Co's Pre-Tax Income?
Pre-Tax Income
898.2m
CNY
898.2m
CNY
Based on the financial report for Dec 31, 2023, Tibet Rhodiola Pharmaceutical Holding Co's Pre-Tax Income amounts to 898.2m CNY.
What is Tibet Rhodiola Pharmaceutical Holding Co's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
40%
40%
Over the last year, the Pre-Tax Income growth was 94%. The average annual Pre-Tax Income growth rates for Tibet Rhodiola Pharmaceutical Holding Co have been 24% over the past three years , 30% over the past five years , and 40% over the past ten years .
You don't have any saved screeners yet
